coderm-research-logo380px

CODerm Research:  303.761.0906

(option 6)

Active Clinic Trials

abbvie-eczema-ad

(1) Atopic Dermatitis (Eczema)

Eczema doesn’t have to control your life. If you are struggling with the symptoms of moderate to severe atopic dermatitis, a study involving a once daily oral pill in combination with topical corticosteroids could be an option for you.

Qualified participants include:

  • Adolescents and adults aged 12 to 75 years (minimum weight of 88 pounds)
  • Those with chronic moderate to severe symptoms that started at least 3 years from planned study start date
  • No prior Dupixent usage

Those that qualify will:

  • Receive study-related care from a board certified physician and other medical staff at no cost
  • Receive payment for each visit
czpl-eczema

(2) Atopic Dermatitis (Eczema)

Do you suffer from moderate to severe Atopic Dermatitis (Eczema)?  If so, you may qualify for a clinical trial studying the effectiveness of a once daily investigational oral pill for moderate to severe atopic dermatitis.

Qualified participants include:

  • Adults aged 18 and up

Those that qualify will:

  • Receive study treatment from a board certified dermatologist at no cost
  • Will be compensated for their time, per visit
concert-cp543.2003

(3) Alopecia Areata

Do you or someone you know suffer alopecia areata?

Qualified participants:

  • CODerm Research is looking for people between 18 and 65 years old who have alopecia areata (patchy hair loss) to participate in a clinical research study evaluating an investigational oral treatment.

Those that qualify will:

  • Will receive compensation up to $825.  Your participation in this study is at no cost to you.

Interested in participating in a clinical trial?

Please contact us at (303) 761-0906, option 6 or email us at cr@coloradodermatology.com with your name, phone number, date of birth and study of interest.

Sponsors

If you are interested in having CODerm running your study at our site please contact research@coloradodermatology.com.